TYK2 Pseudokinase Inhibitor
Autoimmune Disorders
PreclinicalPreclinical Development
Key Facts
About A2A Pharma
A2A Pharmaceuticals is a private, AI-driven drug discovery company focused on developing first-in-class therapeutics for life-threatening diseases, with a core emphasis on oncology. The company has achieved key milestones, including advancing its lead TACC3 inhibitor (AO-252) into Phase 1 clinical trials with early signs of efficacy and forming strategic partnerships with Biomea Fusion and Johnson & Johnson. Utilizing its SCULPT™ platform, A2A systematically designs novel chemical libraries to drug challenging targets, building a pipeline that includes inhibitors of MLL-Menin, TYK2 pseudokinase, YAP-TEAD, and a KRAS degrader.
View full company profileTherapeutic Areas
Other Autoimmune Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira | Royalty Pharma | Commercial |
| Immunomodulation Programs | Fosun Pharma | Various Phases |
| Adalimumab Biosimilar | Glenmark Pharmaceuticals | Phase 3 |
| Autoimmune Disease Programs | TScan Therapeutics | Discovery |
| Autoimmune Diagnostics (Immco) | Trinity Biotech | Approved/Commercial |